Description: BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
Home Page: www.bioinvent.com
The Gamma Building
Lund,
223 70
Sweden
Phone:
46 4 62 86 85 50
Officers
Name | Title |
---|---|
Dr. Martin Welschof Ph.D. | Pres & CEO |
Mr. Stefan Ericsson M.B.A. | Chief Financial Officer |
Ms. Marie Moores M.Sc., R.G.N. | Chief Operating Officer |
Mr. Kristoffer Rudenholm Hansson | Sr. VP of Technical Operations |
Mr. Björn Frendéus | Chief Scientific Officer |
Ms. Cecilia Hofvander | Sr. Director of Investor Relations |
Dr. Andres McAllister | Chief Medical Officer |
Ms. Ingrid Teige | Head of Preclinical Research |
Ms. Sylvie Ryckebusch | Chief Bus. Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.4002 |
Price-to-Sales TTM: | 7.2531 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 93 |